我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

胃复春联合HP根除术治疗幽门螺杆菌相关慢性萎缩性胃炎有效性和安全性的Meta分析(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2020年05期
页码:
36-42
栏目:
临床研究
出版日期:
2020-12-30

文章信息/Info

Title:
Meta-analysis on the Efficacy and Safety of Weifuchun Combined withHP Eradication in the Treatment of Helicobacter PyloriAssociated Chronic Atrophic Gastritis
文章编号:
1000-2723(2020)05-0036-07
作者:
魏凌云1李健2李海文2王宏艳2何祥忠3郑一沣3黄穗平3
1. 广州中医药大学第四临床医学院,广东 深圳 518033;2. 深圳市中医院,广东 深圳 518033;3. 广州中医药大学,广东 广州 510000
Author(s):
WEI Lingyun1 LI Jian2 LI Haiwen2 WANG Hongyan2 HE Xiangzhong3 ZHENG Yifeng3 HUANG Suiping3
1. The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China;2. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033,China;3. Guangzhou University of Chinese Medicine, Guangzhou 510000, China
关键词:
幽门螺旋杆菌胃复春联合HP根除率总体疗效率Meta分析萎缩性胃炎
Keywords:
Helicobacter pylori Weifuchun combination HP eradication rate overall therapeutic efficiency Meta-analysis atrophic gastritis
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2020.05.007
文献标识码:
A
摘要:
目的〓 大量的研究证明幽门螺杆菌(Helicobacter pylori, HP)与慢性萎缩性胃炎(chronic atrophic gastritis, CAG)关系密切,临床上常将根除HP作为慢性萎缩性胃炎治疗的关键环节。但是随着近年来HP根除疗法耐药率的升高,中药的杀菌、抑菌作用被重点突出。近年来,有关于中药与西药联合运用以提高HP根除率的文献报道不断增加。为此,本文系统地评价胃复春联合HP根除术对于HP相关慢性萎缩性胃炎的治疗有效性、安全性。方法 检索万方数据库、CNKI、维普、Cochrane Library、PubMed及Embase等数据库中有关胃复春联合HP根除疗法治疗CAG的随机对照试验,日期为2001年1月至2020年8月。对于纳入的文献进行资料提取以及质量评价,共纳入的9篇文献采用改进Jadad量表做系统质量评价。采用RevMan5.3软件对纳入文献的HP根除率、不良反应发生率、总体疗效率行Meta系统评价。结果 ①共纳入9篇随机对照试验,有3项高质量文献,剩余均为低质量文献。②Meta结果,联合组在HP根除率上[MD=3.41,95%CI(2.23,5.19),Z=5.70,P<0.000 01];不良反应发生率上[MD=0.37,95%CI(0.18,0.79),Z=2.57,P=0.01];总体疗效率[MD=3.88,95%CI(2.68,5.62),Z=7.16,P<0.000 01]方面都是优于不联合组。结论 胃复春联合HP根除术组在HP根除率、不良反应发生率以及总体疗效率方面均有显著性意义。说明对于CAG的治疗,在HP根除治疗的基础上联合胃复春可以进一步提高HP根除率、总体疗效率,并减少不良反应发生率。但因纳入的文献整体数量不多、文章的质量不高,需更多大样本、多中心的随机对照试验来进一步提供有效数据。
Abstract:
Objective A large number of studies have demonstrated that Helicobacter Pylori(HP) is closely related to chronic atrophic gastritis(CAG), and the eradication of HP is often regarded as a key link in the clinical treatment of chronic atrophic gastritis. However, with the increase of drug resistance rate of HP eradication therapy in recent years, the bactericidal and bacteriostatic effects of traditional Chinese medicine have been highlighted. In recent years, there have been increasing reports on the combination of traditional Chinese medicine and western medicine to improve the eradication rate of HP. To this end, this paper systematically evaluated the efficacy and safety of Weifuchun combined with HP eradication in the treatment of HP-related chronic atrophic gastritis. Methods Randomized controlled trials of gastroenterol combined with HP eradication therapy for CAG from January 2001 to August 2020 were searched using computer systems from Wanfang Database, CNKI, Viper, Cochrane Library, PubMed and Embase databases. Data extraction and quality evaluation were carried out for the included literatures. A total of 9 included literatures were systematically evaluated by using the improved Jadad scale. The HP eradication rate, adverse reaction rate and overall efficacy rate in the included literature were Meta systematic evaluation using RevMan 5.3 software. Results ① A total of 9 randomized controlled trials were included, of which 3 were of high quality and the rest were of low quality. ② Meta results: the eradication rate of HP in the combined group[MD=3.41,95%CI(2.23,5.19),Z=5.70,P<0.000 01]. The incidence of adverse reactions was[MD=0.37,95%CI(0.18,0.79),Z=2.57,P=0.01]. The overall efficacy rate [MD=3.88,95%CI(2.68,5.62),Z=7.16,P<0.000 01] was superior to the non-combined group. Conclusion HP eradication rate, adverse reaction rate and overall efficacy rate were significant in the group of gastroenterology combined with HP eradication. It indicates that for the treatment of CAG, the combination of HP eradication and gastroenterology on the basis of HP eradication treatment can further improve the eradication rate and overall efficacy rate of HP, and reduce the incidence of adverse reactions. However, due to the small number of included literatures and the low quality of the articles, more large sample and multi-center randomized controlled trials are needed to provide further effective data.

参考文献/References

[1] OHATA H,KITAUCHI S,YOSHIMURA N,et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer[J]. Int J Cancer,2004,109(1):138-143.
[2] DU Y,BAI Y,XIE P,et al. Chronic gastritis in China:a national multi-center survey[J]. BMC Gastroenterol,2014,14:21.
[3] 房静远,陈萦晅,高琴琰. 重视慢性萎缩性胃炎癌变的预警、早诊与预防[J]. 中华消化杂志,2018,38(3):145-148.
[4] 杨佳卉,梁雨,罗培培,等. 荆花胃康联合三联或四联疗法与四联疗法对比治疗幽门螺杆菌相关慢性胃炎或消化性溃疡有效性和安全性的Meta分析[J]. 中国全科医学,2019,22(17):2091-2098.
[5] FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al. Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):E359-E386.
[6] 殷静,易晋宇,徐波,等. 血瘀理论与慢性萎缩性胃炎的诊治[J]. 中华中医药学刊,2019,37(3):624-627.
[7] 李海文. 胃萎清治疗慢性萎缩性胃炎的临床疗效及作用机制研究[D]. 广州:广州中医药大学,2017.
[8] 张乐乐,耿雷,林旭荣,等. 养胃颗粒联合四联疗法治疗Hp阳性慢性萎缩性胃炎的临床研究[J]. 中国医药导报,2019,16(8):152-155.
[9] 韦德锋,韦维,刘熙荣,等. 中药及其复方治疗慢性萎缩性胃炎实验与临床研究进展[J]. 山东中医杂志,2018,37(10):869-871.
[10] MALFERTHEINER P,MEGRAUD F,O’MORAIN C A,et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J]. Gut,2017,66(1):6-30.
[11] DEN HOLLANDER W J,KUIPERS E J. Current pharmacotherapy options for gastritis[J]. Expert Opin Pharmacother,2012,13(18):2625-2636.
[12] LI H Z,WANG H,WANG G Q,et al. Treatment of gastric precancerous lesions with Weiansan[J]. World J Gastroenterol,2006,12(33):5389-5392.
[13] 李军祥,陈誩,吕宾,等. 慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志,2018,26(2):121-131.
[14] 陈文剑. 丽珠胃三联联合胃复春在HP阳性萎缩性胃炎治疗中的应用评价[J]. 北方药学,2015,12(4):22-23.
[15] 黄晓宇. 四联疗法联合胃复春在Hp阳性慢性萎缩性胃炎治疗中的效果观察[J]. 临床医药文献电子杂志,2017,4(52):10276-10277.
[16] 袁裕龙,吴彩霞. 四联疗法联合胃复春在慢性萎缩性胃炎治疗中的效果分析[J]. 基层医学论坛,2020,24(13):1922-1923.
[17] 董安山,潘兆宝,吉华青,等. 四联疗法联合胃复春在慢性萎缩性胃炎治疗中的效果观察[J]. 重庆医学,2017,46(9):1257-1258.
[18] 贺海峰,白永胜. 四联疗法联合胃复春治疗慢性萎缩性胃炎伴幽门螺旋杆菌感染的临床效果及对血清炎性因子的影响[J]. 临床医学研究与实践,2020,5(12):127-129.
[19] 唐旖旎,潘亚敏,薛仕贵,等. 胃复春联合三联疗法治疗慢性萎缩性胃炎患者的临床疗效及对血清胃泌素、胃动素及降钙素原水平的影响[J]. 现代生物医学进展,2019,19(10):1903-1906.
[20] 张莹. 胃复春联合四联疗法治疗CAG疗效及对Hp阴转率的影响[J]. 首都食品与医药,2019,26(8):67-68.
[21] 李胜旭. 中西医结合治疗慢性萎缩性胃炎伴幽门螺杆菌感染疗效观察[J]. 江西医药,2013,48(12):1145-1147.
[22] 李川,闵翠兰,丁狼. 中药联合四联疗对脾胃湿热证慢性萎缩性胃炎及胃癌前病变126例临床研究[J]. 药品评价,2019,16(17):81-82.
[23] SONG H,EKHEDEN I G,ZHENG Z,et al. Incidence of gastric cancer among patients with gastric precancerous lesions:observational cohort study in a low risk Western population[J]. BMJ,2015,351:h3867.
[24] LAHNER E,ZAGARI R M,ZULLO A,et al. Chronic atrophic gastritis:Natural history,diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists[AIGO],the Italian Society of Digestive Endoscopy[SIED],the Italian Society of Gastroenterology[SIGE], and the Italian Society of Internal Medicine[SIMI][J]. Dig Liver Dis,2019,51(12):1621-1632.
[25] 杨军,郎海波,高峰,等. 幽门螺杆菌核酸联合分型检测与胃和十二指肠良性疾病严重程度的关系[J]. 中国医药,2018,13(11):1696-1699.
[26] EL-OMAR E M,CARRINGTON M,CHOW W H,et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer[J]. Nature,2000,404(6776):398-402.
[27] LIU W Z,XIE Y,LU H,et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection[J]. Helicobacter,2018,23(2):e12475.
[28] 石鹏,姚洁. 黄连素联合四联疗法治疗幽门螺杆菌阳性消化性溃疡的效果及机制探讨[J]. 中国医药导报,2019,16(22):77-79.
[29] LU B,CHEN M T,FAN Y H,et al. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia:a 3-year follow-up study[J]. World J Gastroenterol,2005,11(41):6518-6520.
[30] 王波玲,高峰. 标准三联与四联方案根除幽门螺杆菌感染成本-效果分析[J]. 中国全科医学,2016,19(11):1237-1241.
[31] MEGRAUD F,COENEN S,VERSPORTEN A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption[J]. Gut,2013, 62(1):34-42.
[32] 张世洋,刘美辰,唐飞,等. 人参配伍白术前后皂苷成分及治疗慢性萎缩性胃炎的活性比较[J]. 中药药理与临床,2019,35(1):117-121.
[33] 张也青,柯樱,叶冠. 胃复春片治疗慢性萎缩性胃炎及胃癌前病变的临床应用和研究现状[J]. 上海医药,2018,39(7):43-46.
[34] 王淋,杨慧萍,朱梦佳,等. 柴胡疏肝散加减治疗慢性萎缩性胃炎肝胃不和证的Meta分析[J]. 云南中医学院学报,2020,43(1):26-33.
[35] 许博,韩吉. 慢性萎缩性胃炎伴异型增生病因病机研究进展[J]. 亚太传统医药,2018,14(6):130-131.
[36] 廖纬琳,陈国忠,胡辉,等. 胃复春治疗慢性萎缩性胃炎的Meta分析[J]. 辽宁中医杂志,2015,42(1):11-15.
[37] 毛阿芳,叶振昊,黄俊敏,等. 黄穗平教授补土论治慢性萎缩性胃炎经验[J]. 中国中西医结合消化杂志,2019,27(2):150-152.
[38] 严海, 胡清林, 青廉,等. 参芪扶正注射液联合胃复春对慢性萎缩性胃炎患者血清胃泌素、可溶性白介素-2受体及免疫功能影响[J]. 实用临床医药杂志, 2017, 21(13):174-175.
[39] 谢咚,林玲,韩涛,等. 胃复春片对慢性萎缩性胃炎大鼠模型的防治作用研究[J]. 中国医药导报,2019,16(27):13-17.
[40] GU Z,LING J,CONG J,et al. A review of therapeutic effects and the pharmacological molecular mechanisms of Chinese medicine Weifuchun in treating precancerous gastric conditions[J]. Integr Cancer Ther,2020,19:1534735420953215.
[41] 李萍,李园,李可歆,等. 基于生物分子网络探讨胃复春片治疗慢性萎缩性胃炎的作用机制研究[J]. 世界中西医结合杂志,2020,15(1):48-53.
[42] 曹阳,顾巍杰,杨德才,等. 基于临床流调的慢性萎缩性胃炎发病危险因素研究[J]. 世界科学技术-中医药现代化,2020,22(4):1060-1067.
[43] 郭会玲,高广周,张金卓,等. 慢性萎缩性胃炎患者血清胃蛋白酶原、胃泌素17水平与年龄的相关性分析[J]. 胃肠病学,2018,23(3):169-172.

备注/Memo

备注/Memo:
收稿日期: 2020 - 10- 02
基金项目: 国家自然科学基金项目(81703995),广东省中医药局黄穗平广东省名中医传承工作室项目(粤财社〔2016〕235号),深圳市卫生计生系统科研项目(SZBC2017017) ?/div>
第一作者简介: 魏凌云(1994-),女,在读硕士研究生,研究方向:中西医结合治疗消化系统疾病。?/div>
?通信作者: 李健,E-mail:645153585@qq.com
更新日期/Last Update: 1900-01-01